Sanofi-Aventis eyes Genzyme

Sanofi-Aventis is expected to make a formal takeover offer to Genzyme's board, sources told The Wall Street Journal.

Sanofi-Aventis is expected to make a formal takeover offer to Genzyme's board, sources told The Wall Street Journal.

Rumors about the possible M&A activity started late last week, with the Journal identifying Genzyme as a target for the French pharmaceutical industry. Key factors at play for Genzyme include its specialization in creating "complex therapies for rare illnesses," something Xconomy notes could make things difficult for generic drug companies down the line.

Genzyme's market value is estimated at $16.7 billion.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in